Clinical studies

• Endpoints: choosing endpoints that will appropriately describe disease progression, amelioration or stability facing new therapeutic modalities.
• Ethical dilemmas of investigators participating in clinical studies related to the autonomy of patient physician relationship.

	Academia-industry-regulatory bodies relationship: the influence of the pharmaceutical industry and regulatory bodies on research topics and methodologies in academic institutions.
	Developmental costs: unrealistic expectations of development by inventors as opposed to the real price/time in the industrial world.
	Alternative medicine: the promise and deception

• Regulated conventional vs. Unregulated alternative medicine
• Patient education
• Evidence based practice
• Are vitamins harmless?

• Patients benefits and drawbacks
• Managing patients that do not meet "inclusion criteria" of "well controlled" studies
• Are all studies created equal? Hidden biases - can we tell?
• Meta - analyses